One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
1289.23.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Covance, Leeds, United Kingdom
PAREXEL International GmbH, Berlin, Germany
Research Site, Manchester, United Kingdom
Parexel Early Phase Clinical Unit, Harrow, United Kingdom
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
Siteman Cancer Center - South County, Saint Louis, Missouri, United States
FR801, Rennes, France
Johns Hopkins School of Medicine, Department of Dermatology, Baltimore, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.